Navigation Links
New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
Date:3/31/2009

NEW YORK, March 31 /PRNewswire/ -- Transdermal delivery of estrogen therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests. The study was conducted by researchers at NYU Langone Medical Center and was published in the latest issue of Menopause: The Journal of the North American Menopause Society.

Prescription transdermal estrogen therapy is bioidentical to estrogen produced by a woman's ovaries before menopause and delivered through the skin. Transdermal estrogen is available in a variety of formulations which have been quality controlled and approved safe and effective by the United States Food and Drug Administration (FDA).

The team at NYU Langone sought to determine the effects of delivery of estrogen therapy on postmenopausal women. Blood obtained from 84 postmenopausal women was tested for clotting activity before and after administration of oral or transdermal estrogen for a period of eight weeks. Women with borderline clotting issues showed "a significant acceleration" of clotting after oral estrogen therapy, but no significant change after transdermal estrogen therapy.

"Venous thromboembolic complications or blood clots represent an established risk factor of estrogen therapy, and evidence is now mounting that the route of estrogen administration influences this risk," said researcher Lila Nachtigall, M.D., Director of the Women's Wellness Program at NYU. "These new data on the safety of transdermal HT delivery may prove to be useful information for postmenopausal women deciding whether to take estrogen therapy and whether to take it orally or through the skin."

The research team studied platelet activity in the study participants' blood. Platelets serve a central role in forming pathological arterial thrombosis that causes myocardial infarction and stroke. The study's authors further concluded that the ability to identify postmenopausal women with an increased risk of arterial thrombosis or clotting before even starting estrogen therapy is an important goal to help physicians determine which women may be at the least risk to benefit from estrogen therapy.

"The effect of estrogen therapy on cardiovascular risk remains a point of controversy; however, these data suggest that estrogen delivered transdermally may not increase the likelihood of clotting for women who are at borderline risk," said Dr. Nachtigall. "This study supports the emerging data suggesting that oral, not transdermal estrogen may increase the risk of venous thromboembolism in postmenopausal women."

Transdermal estrogen therapies available by prescription offer effective, low-dose estrogen for the treatment of moderate to severe hot flashes associated with menopause and are administered in the form of gels, sprays and patches. Some include: estradiol gel 0.1% available in three doses 0.25, 0.5, and 1.0 mg estradiol; estradiol patches available in .025mg, .0375mg, .05mg, .075mg; and .1mg a transdermal estradiol mist spray. For more information about menopause management visit: www.menopause.org.

About NYU Langone Medical Center

Located in the heart of New York City, NYU Langone Medical Center is a premier center for health care, biomedical research, and medical education. For over 167 years, NYU physicians and researchers have contributed to the practice and science of medicine. Today the Medical Center consists of NYU School of Medicine; Rusk Institute of Rehabilitation Medicine, the first and largest facility of its kind; NYU Hospital for Joint Diseases, a leader in musculoskeletal care; and such nationally recognized programs as the NYU Cancer Institute, the NYU Child Study Center, and the NYU Cardiac and Vascular Institute.


'/>"/>
SOURCE NYU Langone Medical Center
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... PUNE , Maharashtra, February 12, 2016 /PRNewswire/ ... Market research report titled Chronic Inflammation Global ... and a snapshot of the global clinical trials ... the clinical trials by Region, Country (G7 & ... End point status and reviews top companies involved ...
(Date:2/11/2016)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... Company also filed its Quarterly Report on Form 10-Q for ... and Exchange Commission today. --> ... --> --> Net sales for the three ... to $5.4 million from $2.8 million for the three months ...
(Date:2/11/2016)... Feb. 11, 2016  Governor Andrew M. Cuomo today ... 1,400 jobs throughout Western New York ... the SUNY Polytechnic Institute, includes a major expansion of ... Buffalo , as well as the ... in Dunkirk . The combined projects ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of coconut water beverages ... GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature ... event. The invitation-only gifting suite, held this year at the W Hollywood Hotel, has ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, ... to offer real-time business intelligence (BI) to their small and medium business (SMB) ...
(Date:2/12/2016)... ... 12, 2016 , ... AssureVest Insurance Group, a locally owned insurance firm with ... will raise funds earmarked to purchase computers and software for Mrs. Harrison’s 2nd and ... is in a low-income area and has more than 60 2nd and 3rd graders ...
(Date:2/12/2016)... Columbus, OH (PRWEB) , ... February 12, 2016 , ... ... families of the greater Columbus, OH area. The latest campaign focuses on the fight ... the disease. Donations are now being accepted here . , Carmen is a ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Miami Dental Specialists ... to their Miami dental office. Beginning in January, Miami Dental Specialists will offer ... Dental Specialists are the first office to be chosen by the dental implant manufacturer, ...
Breaking Medicine News(10 mins):